Grayson B, Leger M, Piercy C, et al. Assessment of disease-related cognitive impairments using the novel object recognition (NOR) task in rodents. Behav Brain Res. 2015;285:176–93.
Vannorsdall TD. Cognitive Changes Related to Cancer Therapy. Med Clin N Am. 2017;101(6):1115–34.
Jim HSL, Phillips KM, Chait S, et al. Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol. 2012;30(29):3578–87.
Raffa RB. A proposed mechanism for chemotherapy-related cognitive impairment (‘chemo-fog’). J Clin Pharm Ther. 2011;36(3):257–9.
Cerulla Torrente N, Navarro Pastor J, de la Osa Chaparro N. Systematic review of cognitive sequelae of non-central nervous system cancer and cancer therapy. J Cancer Surviv. 2020;14(4):464–82.
Wefel JS, Vardy J, Ahles T, et al. International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol. 2011;12(7):703–8.
Cheung YT, Lim SR, Ho HK, et al. Cytokines as mediators of chemotherapy-associated cognitive changes: current evidence, limitations and directions for future research. Plos One. 2013;8(12): e81234.
Ongnok B, Chattipakorn N, Chattipakorn SC. Doxorubicin and cisplatin induced cognitive impairment: the possible mechanisms and interventions. Exp Neurol. 2020;324:113118.
Deprez S, Kesler SR, Saykin AJ, et al. International cognition and cancer task force recommendations for neuroimaging methods in the study of cognitive impairment in non-CNS cancer patients. JNCI J Natl Cancer Inst. 2018;110(3):223–31.
Wang X, Huang W, Su L, et al. Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer’s disease. Mol Neurodegener. 2020;15(1):1–27.
Walczak P, Janowski M. Chemobrain as a product of growing success in chemotherapy—focus on glia as both a victim and a cure. Neuropsychiatry. 2019;9(1):2207–16.
Seigers R, Fardell JE. Neurobiological basis of chemotherapy-induced cognitive impairment: a review of rodent research. Neurosci Biobehav Rev. 2011;35(3):729–41.
Silberfarb PM, Philibert D, Levine PM. Psychosocial aspects of neoplastic disease: II. Affective and cognitive effects of chemotherapy in cancer patients. Am J Psychiatry. 1980;137(5):597–601.
van Dam FS, Schagen SB, Muller MJ, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst. 1998;90(3):210–8.
Freeman JR, Broshek DK. Assessing cognitive dysfunction in breast cancer: what are the tools? Clin Breast Cancer. 2002;3:S91–9.
Harder H, Holtel H, Bromberg JEC, et al. Cognitive status and quality of life after treatment for primary CNS lymphoma. Neurology. 2004;62(4):544–7.
Schagen SB, Boogerd W, Muller MJ, et al. Cognitive complaints and cognitive impairment following BEP chemotherapy in patients with testicular cancer. Acta Oncol. 2009;47(1):63–70.
Cheng H, Yang Z, Dong B, et al. Chemotherapy-induced prospective memory impairment in patients with breast cancer. Psychooncology. 2013;22(10):2391–5.
Winocur G, Johnston I, Castel H. Chemotherapy and cognition: International cognition and cancer task force recommendations for harmonising preclinical research. Cancer Treat Rev. 2018;69:72–83.
Bolton G, Isaacs A. Women’s experiences of cancer-related cognitive impairment, its impact on daily life and care received for it following treatment for breast cancer. Psychol Health Med. 2018;23(10):1261–74.
Von Ah D, Tallman EF. Perceived cognitive function in breast cancer survivors: evaluating relationships with objective cognitive performance and other symptoms using the functional assessment of cancer therapy-cognitive function instrument. J Pain Symptom Manage. 2015;49(4):697–706.
Park J, Bae SH, Jung YS, et al. The psychometric properties of the Korean version of the functional assessment of cancer therapy-cognitive (FACT-Cog) in Korean patients with breast cancer. Support Care Cancer. 2015;23(9):2695–703.
Dueck AC, Mendoza TR, Mitchell SA, et al. Validity and reliability of the US National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). JAMA Oncol. 2015;1(8):1051.
Moore K, Stutzman S, Priddy L, et al. A pilot study exploring the severity and onset of chemotherapy-related cognitive impairment. Clin J Oncol Nurs. 2019;23(4):411–6.
Shilling V, Jenkins V, Trapala IS. The (mis)classification of chemo-fog-methodological inconsistencies in the investigation of cognitive impairment after chemotherapy. Breast Cancer Res Treat. 2006;95(2):125–9.
Vardy J, Wong K, Yi Q, et al. Assessing cognitive function in cancer patients. Support Care Cancer. 2006;14(11):1111–8.
Gifford AR, Lawrence JA, Baker LD, et al. National Institute on Aging/Alzheimer’s association criteria for mild cognitive impairment applied to chemotherapy treated breast cancer survivors. J Oncol Res. 2017;1(1):101.
Dyk KV, Crespi CM, Petersen L, et al. Identifying cancer-related cognitive impairment using the FACT-Cog perceived cognitive impairment. JNCI Cancer Spectrum. 2020;4(1):pkz099.
Collins B, Mackenzie J, Kyeremanteng C. Study of the cognitive effects of chemotherapy: Considerations in selection of a control group. J Clin Exp Neuropsyc. 2013;35(4):435–44.
Nelson WL, Suls J. New approaches to understand cognitive changes associated with chemotherapy for non-central nervous system tumors. J Pain Symptom Manage. 2013;46(5):707–21.
O’Farrell E, Smith A, Collins B. Objective-subjective disparity in cancer-related cognitive impairment: does the use of change measures help reconcile the difference? Psychooncology. 2017;26(10):1667–74.
Lee GD. Transient improvement in cognitive function and synaptic plasticity in rats following cancer chemotherapy. Clin Cancer Res. 2006;12(1):198–205.
Fardell JE, Vardy J, Monds LA, et al. The long-term impact of oxaliplatin chemotherapy on rodent cognition and peripheral neuropathy. Behav Brain Res. 2015;291:80–8.
Rendeiro C, Sheriff A, Bhattacharya TK, et al. Long-lasting impairments in adult neurogenesis, spatial learning and memory from a standard chemotherapy regimen used to treat breast cancer. Behav Brain Res. 2016;315:10–22.
Chiang ACA, Huo X, Kavelaars A, et al. Chemotherapy accelerates age-related development of tauopathy and results in loss of synaptic integrity and cognitive impairment. Brain Behav Immun. 2019;79:319–25.
Li C, Niu J, Zhou B, et al. Dexmedetomidine attenuates cisplatin-induced cognitive impairment by modulating miR-429-3p expression in rats. 3 Biotech. 2020;10(6):244.
Deyama S, Li X, Duman RS. Neuron-specific deletion of VEGF or its receptor Flk-1 impairs recognition memory. Eur Neuropsychopharm. 2020;31:145–51.
Moore HC, Parsons MW, Yue GH, et al. Electroencephalogram power changes as a correlate of chemotherapy-associated fatigue and cognitive dysfunction. Support Care Cancer. 2014;22(8):2127–31.
Schagen SB, Hamburger HL, Muller MJ, et al. Neurophysiological evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function. J Neurooncol. 2001;51(2):159–65.
Kreukels BP, van Dam FS, Ridderinkhof KR, et al. Persistent neurocognitive problems after adjuvant chemotherapy for breast cancer. Clin Breast Cancer. 2008;8(1):80–7.
Simó M, Gurtubay-Antolin A, Vaquero L, et al. Performance monitoring in lung cancer patients pre- and post-chemotherapy using fine-grained electrophysiological measures. NeuroImage Clin. 2018;18:86–96.
Perrier J, Viard A, Levy C, et al. Longitudinal investigation of cognitive deficits in breast cancer patients and their gray matter correlates: impact of education level. Brain Imaging Behav. 2020;14(1):226–41.
Henneghan A, Rao V, Harrison RA, et al. Cortical brain age from pre-treatment to post-chemotherapy in patients with breast cancer. Neurotox Res. 2020;37(4):788–99.
Chen BT, Sethi SK, Jin T, et al. Assessing brain volume changes in older women with breast cancer receiving adjuvant chemotherapy: a brain magnetic resonance imaging pilot study. Breast Cancer Res. 2018;20(1):38.
Kesler S, Janelsins M, Koovakkattu D, et al. Reduced hippocampal volume and verbal memory performance associated with interleukin-6 and tumor necrosis factor-alpha levels in chemotherapy-treated breast cancer survivors. Brain Behav Immun. 2013;30:S109–16.
Lepage C, Smith AM, Moreau J, et al. A prospective study of grey matter and cognitive function alterations in chemotherapy-treated breast cancer patients. Springerplus. 2014;3:444.
Apple AC, Ryals AJ, Alpert KI, et al. Subtle hippocampal deformities in breast cancer survivors with reduced episodic memory and self-reported cognitive concerns. Neuroimage Clin. 2017;14:685–91.
Li X, Chen H, Lv Y, et al. Diminished gray matter density mediates chemotherapy dosage-related cognitive impairment in breast cancer patients. Sci Rep UK. 2018;8(1):13801.
Amidi A, Agerbæk M, Wu LM, et al. Changes in cognitive functions and cerebral grey matter and their associations with inflammatory markers, endocrine markers, and APOE genotypes in testicular cancer patients undergoing treatment. Brain Imaging Behav. 2017;11(3):769–83.
Shiroishi MS, Gupta V, Bigjahan B, et al. Brain cortical structural differences between non-central nervous system cancer patients treated with and without chemotherapy compared to non-cancer controls: a cross-sectional pilot MRI study using clinically-indicated scans. Proc SPIE Int Soc Opt Eng. 2017;10572:105720G.
Sales M, Suemoto CK, Apolinario D, et al. Effects of adjuvant chemotherapy on cognitive function of patients with early-stage colorectal cancer. Clin Colorectal Cancer. 2019;18(1):19–27.
Deprez S, Amant F, Yigit R, et al. Chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning in breast cancer patients. Hum Brain Mapp. 2011;32(3):480–93.
Deprez S, Amant F, Smeets A, et al. Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. J Clin Oncol. 2012;30(3):274–81.
Mzayek Y, de Ruiter MB, Oldenburg HSA, et al. Measuring decline in white matter integrity after systemic treatment for breast cancer: omitting skeletonization enhances sensitivity. Brain Imaging Behav. 2020;15(3):1191–200.
Menning S, de Ruiter MB, Veltman DJ, et al. Changes in brain white matter integrity after systemic treatment for breast cancer: a prospective longitudinal study. Brain Imaging Behav. 2018;12(2):324–34.
Chen BT, Ye N, Wong CW, et al. Effects of chemotherapy on aging white matter microstructure: a longitudinal diffusion tensor imaging study. J Geriatr Oncol. 2020;11(2):290–6.
Billiet T, Emsell L, Vandenbulcke M, et al. Recovery from chemotherapy-induced white matter changes in young breast cancer survivors? Brain Imaging Behav. 2018;12(1):64–77.
Sleurs C, Lemiere J, Christiaens D, et al. Advanced MR diffusion imaging and chemotherapy-related changes in cerebral white matter microstructure of survivors of childhood bone and soft tissue sarcoma? Hum Brain Mapp. 2018;39(8):3375–87.
Inagaki M, Yoshikawa E, Matsuoka Y, et al. Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer Am Cancer Soc. 2007;109(1):146–56.
Simó M, Root JC, Vaquero L, et al. Cognitive and brain structural changes in a lung cancer population. J Thorac Oncol. 2015;10(1):38–45.
Blommaert J, Schroyen G, Vandenbulcke M, et al. Age-dependent brain volume and neuropsychological changes after chemotherapy in breast cancer patients. Hum Brain Mapp. 2019;40(17):4994–5010.
Kesler SR, Gugel M, Huston-Warren E, et al. Atypical structural connectome organization and cognitive impairment in young survivors of acute lymphoblastic leukemia. Brain Connectivity. 2016;6(4):273–82.
Zeng Y, Cheng ASK, Song T, et al. Subjective cognitive impairment and brain structural networks in Chinese gynaecological cancer survivors compared with age-matched controls: a cross-sectional study. BMC Cancer. 2017;17(1):796.
Amidi A, Hosseini SMH, Leemans A, et al. Changes in brain structural networks and cognitive functions in testicular cancer patients receiving cisplatin-based chemotherapy. JNCI J Natl Cancer Inst 2017;109 (12).
Wang L, Zou L, Chen Q, et al. Gray matter structural network disruptions in survivors of acute lymphoblastic leukemia with chemotherapy treatment. Acad Radiol. 2020;27(3):e27–34.
Liu S, Yin N, Ma R, et al. Abnormal topological characteristics of brain white matter network relate to cognitive and emotional deficits of non-small cell lung cancer (NSCLC) patients prior to chemotherapy. Int J Neurosci. 2020;1–10.
de Ruiter MB, Reneman L, Boogerd W, et al. Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Hum Brain Mapp. 2011;32(8):1206–19.
Scherling C, Collins B, Mackenzie J, et al. Prechemotherapy differences in response inhibition in breast cancer patients compared to controls: a functional magnetic resonance imaging study. J Clin Exp Neuropsychol. 2012;34(5):543–60.
Vardy JL, Stouten-Kemperman MM, Pond G, et al. A mechanistic cohort study evaluating cognitive impairment in women treated for breast cancer. Brain Imaging Behav. 2019;13(1):15–26.
Scherling C, Collins B, MacKenzie J, et al. Pre-chemotherapy differences in visuospatial working memory in breast cancer patients compared to controls: an fMRI study. Front Hum Neurosci. 2011;I:5.
Campbell KL, Kam J, Neil-Sztramko SE, et al. Effect of aerobic exercise on cancer-associated cognitive impairment: a proof-of-concept RCT. Psychooncology. 2018;27(1):53–60.
Dumas JA, Makarewicz J, Schaubhut GJ, et al. Chemotherapy altered brain functional connectivity in women with breast cancer: a pilot study. Brain Imaging Behav. 2013;7(4):524–32.
Askren MK, Jung M, Berman MG, et al. Neuromarkers of fatigue and cognitive complaints following chemotherapy for breast cancer: a prospective fMRI investigation. Breast Cancer Res Treat. 2014;147(2):445–55.
Jung MS, Zhang M, Askren MK, et al. Cognitive dysfunction and symptom burden in women treated for breast cancer: a prospective behavioral and fMRI analysis. Brain Imaging Behav. 2017;11(1):86–97.
Conroy SK, McDonald BC, Smith DJ, et al. Alterations in brain structure and function in breast cancer survivors: effect of post-chemotherapy interval and relation to oxidative DNA damage. Breast Cancer Res Treat. 2013;137(2):493–502.
Root JC, Pergolizzi D, Pan H, et al. 2020. Prospective evaluation of functional brain activity and oxidative damage in breast cancer: changes in task-induced deactivation during a working memory task. Brain Imaging Behav.
Wang L, Apple AC, Schroeder MP, et al. Reduced prefrontal activation during working and long-term memory tasks and impaired patient-reported cognition among cancer survivors post chemotherapy compared with healthy controls. Cancer Am Cancer Soc. 2016;122(2):258–68.
Stefancin P, Cahaney C, Parker RI, et al. Neural correlates of working memory function in pediatric cancer survivors treated with chemotherapy: an fMRI study. NMR Biomed. 2020;33(6): e4296.
Miao H, Li J, Hu S, et al. Long-term cognitive impairment of breast cancer patients after chemotherapy: a functional MRI study. Eur J Radiol. 2016;85(6):1053–7.
Chen BT, Jin T, Patel SK, et al. Intrinsic brain activity changes associated with adjuvant chemotherapy in older women with breast cancer: a pilot longitudinal study. Breast Cancer Res Treat. 2019;176(1):181–9.
Kardan O, Reuter-Lorenz PA, Peltier S, et al. Brain connectivity tracks effects of chemotherapy separately from behavioral measures. Neuroimage Clin. 2019;21:101654.
Chen H, Ding K, Zhao J, et al. The dorsolateral prefrontal cortex is selectively involved in chemotherapy-related cognitive impairment in breast cancer patients with different hormone receptor expression. Am J Cancer Res. 2019;9(8):1776–85.
Van der Gucht K, Ahmadoun S, Melis M, et al. Effects of a mindfulness-based intervention on cancer-related cognitive impairment: results of a randomized controlled functional magnetic resonance imaging pilot study. Cancer Am Cancer Soc. 2020;126(18):4246–55.
Chen L, Zhan Y, He F, et al. Altered functional connectivity density in young survivors of acute lymphoblastic leukemia using resting-state fMRI. Cancer Manage Res. 2020;12:7033–41.
Chen L, Zhan Y, He F, et al. Altered functional connectivity density in young survivors of acute lymphoblastic leukemia using resting-state fMRI. Cancer Manage Res. 2020;12:7033–41.
Piccirillo JF, Hardin FM, Nicklaus J, et al. Cognitive impairment after chemotherapy related to atypical network architecture for executive control. Oncology. 2015;88(6):360–8.
Kesler SR, Blayney DW. Neurotoxic Effects of anthracycline-vs non anthracycline-based chemotherapy on cognition in breast cancer survivors. JAMA Oncol. 2016;2(2):185.
Cheng H, Li W, Gong L, et al. Altered resting-state hippocampal functional networks associated with chemotherapy-induced prospective memory impairment in breast cancer survivors. Sci Rep UK. 2017;7(1):45135.
Miao H, Chen X, Yan Y, et al. Functional connectivity change of brain default mode network in breast cancer patients after chemotherapy. Neuroradiology. 2016;8(9):921–8.
Chen VC, Lin K, Tsai Y, et al. Connectome analysis of brain functional network alterations in breast cancer survivors with and without chemotherapy. PLOS One. 2020;15(5): e232548.
Zhang Y, Chen Y, Hu L, et al. Chemotherapy-induced functional changes of the default mode network in patients with lung cancer. Brain Imaging Behav. 2020;14(3):847–56.
Feng Y, Wang YF, Zheng LJ, et al. Network-level functional connectivity alterations in chemotherapy treated breast cancer patients: a longitudinal resting state functional MRI study. Cancer Imaging. 2020;20(1):73.
Bruno J, Hosseini SMH, Kesler S. Altered resting state functional brain network topology in chemotherapy-treated breast cancer survivors. Neurobiol Dis. 2012;48(3):329–38.
Phillips NS, Kesler SR, Scoggins MA, et al. Connectivity of the cerebello-thalamo-cortical pathway in survivors of childhood leukemia treated with chemotherapy only. JAMA Netw Open. 2020;3(11): e2025839.
Daugherty AM, Raz N. Appraising the Role of iron in brain aging and cognition: promises and limitations of MRI methods. Neuropsychol Rev. 2015;25(3):272–87.
Chen BT, Ghassaban K, Jin T, et al. Subcortical brain iron deposition and cognitive performance in older women with breast cancer receiving adjuvant chemotherapy: a pilot MRI study. Magn Reson Imaging. 2018;54:218–24.
Rodrigue KM, Daugherty AM, Haacke EM, et al. The role of hippocampal iron concentration and hippocampal volume in age-related differences in memory. Cereb Cortex. 2013;23(7):1533–41.
McDonald BC, Conroy SK, Smith DJ, et al. Frontal gray matter reduction after breast cancer chemotherapy and association with executive symptoms: a replication and extension study. Brain Behav Immun. 2013;30(Suppl):S117–25.
Tong T, Lu H, Zong J, et al. Chemotherapy-related cognitive impairment in patients with breast cancer based on MRS and DTI analysis. Breast Cancer-Tokyo. 2020;27(5):893–902.
Kesler SR, Watson C, Koovakkattu D, et al. Elevated prefrontal myo-inositol and choline following breast cancer chemotherapy. Brain Imaging Behav. 2013;7(4):501–10.
Zeng Y, Cheng ASK, Song T, et al. Effects of acupuncture on cancer-related cognitive impairment in Chinese gynecological cancer patients: a pilot cohort study. Integr Cancer Ther. 2018;17(3):737–46.
Ponto LLB, Menda Y, Magnotta VA, et al. Frontal hypometabolism in elderly breast cancer survivors determined by [18F] fluorodeoxyglucose (FDG) positron emission tomography (PET): a pilot study. Int J Geriatr Psych. 2015;30(6):587–94.
Sorokin J, Saboury B, Ahn JA, et al. Adverse functional effects of chemotherapy on whole-brain metabolism: a PET/CT quantitative analysis of FDG metabolic pattern of the “chemo-brain.” Clin Nucl Med. 2014;39(1):e35–9.
Baudino B, D’Agata F, Caroppo P, et al. The chemotherapy long-term effect on cognitive functions and brain metabolism in lymphoma patients. Q J Nucl Med Mol Imaging. 2012;56(6):559–68.
Eshghi N, Garland LL, Choudhary G, et al. Regional changes in brain (18)F-FDG uptake after prophylactic cranial irradiation and chemotherapy in small cell lung cancer may reflect functional changes. J Nucl Med Technol. 2018;46(4):355–8.
Vitor T, Kozasa EH, Bressan RA, et al. Impaired brain dopamine transporter in chemobrain patients submitted to brain SPECT imaging using the technetium-99m labeled tracer TRODAT-1. Ann Nucl Med. 2019;33(4):269–79.
Gandal MJ, Ehrlichman RS, Rudnick ND, et al. A novel electrophysiological model of chemotherapy-induced cognitive impairments in mice. Neuroscience. 2008;157(1):95–104.
Winocur G, Henkelman M, Wojtowicz JM, et al. The effects of chemotherapy on cognitive function in a mouse model: a prospective study. Clin Cancer Res. 2012;18(11):3112–21.
Winocur G, Berman H, Nguyen M, et al. Neurobiological mechanisms of chemotherapy-induced cognitive impairment in a transgenic model of breast cancer. Neuroscience. 2018;369:51–65.
Berlin C, Lange K, Lekaye HC, et al. Long-term clinically relevant rodent model of methotrexate-induced cognitive impairment. Neuro Oncol. 2020;22(8):1126–37.
Speidell AP, Demby T, Lee Y, et al. Development of a human APOE knock-in mouse model for study of cognitive function after cancer chemotherapy. Neurotox Res. 2019;35(2):291–303.
Demby TC, Rodriguez O, McCarthy CW, et al. A mouse model of chemotherapy-related cognitive impairments integrating the risk factors of aging and APOE4 genotype. Behav Brain Res. 2020;384:112534.
Inoue T, Majid T, Pautler RG. Manganese enhanced MRI (MEMRI): neurophysiological applications. Rev Neurosci. 2011;22(6):675–94.
Shi D, Huang Y, Lai CSW, et al. Chemotherapy-induced cognitive impairment is associated with cytokine dysregulation and disruptions in neuroplasticity. Mol Neurobiol. 2019;56(3):2234–43.
Shi D, Huang Y, Lai CSW, et al. Ginsenoside Rg1 prevents chemotherapy-induced cognitive impairment: associations with microglia-mediated cytokines, neuroinflammation, and neuroplasticity. Mol Neurobiol. 2019;56(8):5626–42.
Keeney JTR, Ren X, Warrier G, et al. Doxorubicin-induced elevated oxidative stress and neurochemical alterations in brain and cognitive decline: protection by MESNA and insights into mechanisms of chemotherapy-induced cognitive impairment (“chemobrain”). Oncotarget. 2018;9(54):30324–39.
Ren X, Keeney JTR, Miriyala S, et al. The triangle of death of neurons: oxidative damage, mitochondrial dysfunction, and loss of choline-containing biomolecules in brains of mice treated with doxorubicin. Advanced insights into mechanisms of chemotherapy induced cognitive impairment (“chemobrain”) involving TNF-α. Free Radic Bio Med. 2019;134:1–8.
Seigers R, Timmermans J, van der Horn HJ, et al. Methotrexate reduces hippocampal blood vessel density and activates microglia in rats but does not elevate central cytokine release. Behav Brain Res. 2010;207(2):265–72.
Lim I, Joung H, Yu AR, et al. PET Evidence of the effect of donepezil on cognitive performance in an animal model of chemobrain. Biomed Res Int. 2016;2016:1–7.
Barry RL, Byun NE, Tantawy MN, et al. In vivo neuroimaging and behavioral correlates in a rat model of chemotherapy-induced cognitive dysfunction. Brain Imaging Behav. 2018;12(1):87–95.
Bai X, Zheng J, Zhang B, et al. Cognitive dysfunction and neurophysiological mechanism of breast cancer patients undergoing chemotherapy based on RS fMRI images. World Neurosurg. 2020;149:406–12.
Mo C, Lin H, Fu F, et al. Chemotherapy-induced changes of cerebral activity in resting-state functional magnetic resonance imaging and cerebral white matter in diffusion tensor imaging. Oncotarget. 2017;8(46):81273–84.
Kesler SR, Ogg R, Reddick WE, et al. Brain network connectivity and executive function in long-term survivors of childhood acute lymphoblastic leukemia. Brain Connectivity. 2018;8(6):333–42.
Cahaney C, Stefancin P, Coulehan K, et al. Anatomical brain MRI study of pediatric cancer survivors treated with chemotherapy: correlation with behavioral measures. Magn Reson Imaging. 2020;72:8–13.
Nudelman KN, Wang Y, McDonald BC, et al. Altered cerebral blood flow one month after systemic chemotherapy for breast cancer: a prospective study using pulsed arterial spin labeling MRI perfusion. PLOS One. 2014;9(5): e96713.
Kesler SR, Rao A, Blayney DW, et al. Predicting long-term cognitive outcome following breast cancer with pre-treatment resting state fMRI and random forest machine learning. Front Hum Neurosci. 2017;11:555.
Chen VC, Lin TY, Yeh DC, et al. Functional and structural connectome features for machine learning chemo-brain prediction in women treated for breast cancer with chemotherapy. Brain Sci. 2020;10(11):851.
Hosseini SM, Kesler SR. Multivariate pattern analysis of FMRI in breast cancer survivors and healthy women. J Int Neuropsychol Soc. 2014;20(4):391–401.
Kesler SR, Petersen ML, Rao V, et al. Functional connectome biotypes of chemotherapy-related cognitive impairment. J Cancer Surviv. 2020;14(4):483–93.
Chen VC, Lin TY, Yeh DC, et al. Predicting chemo-brain in breast cancer survivors using multiple MRI features and machine-learning. Magn Reson Med. 2019;81(5):3304–13.
Henneghan AM, Gibbons C, Harrison RA, et al. Predicting patient reported outcomes of cognitive function using connectome-based predictive modeling in breast cancer. Brain Topogr. 2020;33(1):135–42.
Iuchi T, Shingyoji M, Sakaida T, et al. Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma. Lung Cancer. 2013;82(2):282–7.
Kurihara M, Koda H, Aono H, et al. Rapidly progressive military brain metastasis of lung cancer after EGFR tyrosine kinase inhibitor discontinuation: an autopsy report. Neuropathology. 2019;39(2):147–55.
Zhu J, Zhou R, Xiao H. Mental disorder or conscious disturbance in epidermal growth factor receptor-tyrosine kinase inhibitor treatment of advanced lung adenocarcinoma. Excli J. 2020;19:230–8.
Peled N, Gillis R, Kilickap S, et al. GLASS: global lorlatinib for ALK (+) and ROS1(+) retrospective study: real world data of 123 NSCLC patients. Lung Cancer. 2020;148:48–54.
Lucignani G, Perneczky R. Molecular imaging in cognitive impairment: the relevance of cognitive reserve, importance of multisite longitudinal trials and challenges of standardised analysis. Eur J Nucl Med Mol I. 2010;37(2):399–404.
Albin RL, Burke JF, Koeppe RA, et al. Assessing mild cognitive impairment with amyloid and dopamine terminal molecular imaging. J Nucl Med. 2013;54(6):887–93.
Knezevic D, Mizrahi R. Molecular imaging of neuroinflammation in Alzheimer’s disease and mild cognitive impairment. Prog Neuropsychopharmacol Biol Psychiatry. 2018;80(Pt B):123–31.
Smith GS, Barrett FS, Joo JH, et al. Molecular imaging of serotonin degeneration in mild cognitive impairment. Neurobiol Dis. 2017;105:33–41.
Johnson KA, Minoshima S, Bohnen NI, et al. Update on appropriate use criteria for amyloid PET imaging: Dementia experts, mild cognitive impairment, and education. Alzheimers Dement. 2013;9(4):e106–9.
Lan MJ, Ogden RT, Kumar D, et al. Utility of molecular and structural brain imaging to predict progression from mild cognitive impairment to dementia. J Alzheimers Dis. 2017;60(3):939–47.
Vannini P, Hanseeuw B, Munro CE, et al. Anosognosia for memory deficits in mild cognitive impairment: insight into the neural mechanism using functional and molecular imaging. Neuroimage Clin. 2017;15:408–14.